Placebo to MAS825 100 mg/1 mL Concentrate for solution for infusion / Solution for injection, -, CICLOSPORIN , MAS825
CMAS825D12201
Phase 2 small_molecule active
Quick answer
Placebo to MAS825 100 mg/1 mL Concentrate for solution for infusion / Solution for injection, -, CICLOSPORIN , MAS825 for Autoinflammatory diseases including NLRC4-Gain of Function (GOF) also known as AIFEC (autoinflammation with infantile enterocolitis), X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency, or Cell division control protein 42 homolog (CDC42) mutation. is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Autoinflammatory diseases including NLRC4-Gain of Function (GOF) also known as AIFEC (autoinflammation with infantile enterocolitis), X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency, or Cell division control protein 42 homolog (CDC42) mutation.
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active